Details

Autor(en) / Beteiligte

• Deng, Kai
• Fan, Qinghong
• Yang, Yanhong
• Deng, Xizi
• He, Ruiying
• Tan, Yizhou
• Lan, Yun
• Deng, Xilong
• Pan, Yuejun
• Wang, Yaping
• Guan, Yujuan
• Liu, Huiyuan
• Chen, Fengjuan
• Mo, Xiaoneng
• Tan, Xinghua
• Luo, Chun
• Wen, Xueliang
• Liu, Ying
• Liu, Jinxin
• Zhang, Lieguang
• Tang, Xiaoping
• Hu, Fengyu
• Li, Feng

Titel

Prognostic roles of KL‐6 in disease severity and lung injury in COVID‐19 patients: A longitudinal retrospective analysis

Ist Teil von

• Journal of medical virology, 2021-04, Vol.93 (4), p.2505-2512

Ort / Verlag

United States: Wiley Subscription Services, Inc

Erscheinungsjahr

2021

Quelle

Wiley Blackwell Single Titles

Beschreibungen/Notizen

• To investigate the dynamic changes of Krebs von den Lungen‐6 (KL‐6) among patients with coronavirus disease 2019 (COVID‐19) and the role of KL‐6 as a noninvasive biomarker for predicting long‐term lung injury, the clinical information and laboratory tests of 166 COVID‐19 patients were collected, and a correlation analysis between KL‐6 and other parameters was conducted. There were 17 (10.2%, 17/166) severe/critical and 149 (89.8%, 149/166) mild COVID‐19 patients in our cohort. Serum KL‐6 was significantly higher in severe/critical COVID‐19 patients than in mild patients (median 898.0 vs. 451.2 U/ml, p < .001). KL‐6 was next confirmed to be a sensitive and specific biomarker for distinguishing mild and severe/critical patients and correlate to computed tomography lung lesions areas. Serum KL‐6 concentration during the follow‐up period (>100 days postonset) was well correlated to those concentrations within 10 days postonset (Pearson r = .867, p < .001), indicating the prognostic value of KL‐6 levels in predicting lung injury after discharge. Finally, elevated KL‐6 was found to be significantly correlated to coagulation disorders, and T cells subsets dysfunctions. In summary, serum KL‐6 is a biomarker for assessing COVID‐19 severity and predicting the prognosis of lung injury of discharged patients. Highlights KL‐6 is a biomarker for assessing COVID‐19 severity KL‐6 predicts the prognosis of COVID‐19 patients KL‐6 is associated with CT lung lesions areas.